Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04)

Sex: All

Ages: 50 Years – N/A

Healthy volunteers: No

Phase: PHASE3

Enrollment: 500

Sponsor: Ollin Biosciences, Inc.

Summary

This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with neovascular (wet) age-related macular degeneration (nAMD).

Eligibility Criteria

Inclusion Criteria: * Capable of giving signed informed consent * Be ≥50 years of age * Treatment-naive nAMD in the study eye with active subfoveal choroidal neovascularization (CNV) * Have a decrease in vision in the study eye due to nAMD, with best corrected visual acuity of 78 to 24 letters * Additional inclusion criteria apply Exclusion Criteria: * Be pregnant or breastfeeding * History of cataract surgery in the study eye within 90 days of Screening * Has uncontrolled glaucoma in the study eye * Has uncontrolled hypertension * Has had a stroke or myocardial infarction within 180 days * Additional exclusion criteria apply

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07816315). StuddyBuddy aggregates publicly available trial information.